BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SNY upcoming catalysts

Sanofi: 13 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (5 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 37 readout(s) and 1 FDA event(s). Subscribe to SNY (.ics).

Drugs: Itepekimab, Amlitelimab, Yellow fever vaccine, Mometasone furoate, Dupilumab, rilzabrutinib, PCV21, brivekimig, SAR441566, Measles, combinations, mumps, rubella, live attenuated, Pandemic flu H5 HA mRNA SD2 vaccine, SAR442970, frexalimab, Investigational hMPV/RSV vaccine, Investigational hMPV vaccine, Investigational RSV vaccine, Licensed RSV Vaccine, Investigational RSV, hMPV vaccine, SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab, Isatuximab, Carfilzomib, Dexamethasone, Methylprednisolone, Atezolizumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-25 est.P3Sanofi SNYNCT07216079 Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanImmune Thrombocytopeniaactive not recruiting3
2026-11-28 est.P3Sanofi SNYNCT07103148 A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationYellow Fever Immunizationactive not recruiting2440
2026-12-01 est.P3Sanofi Pasteur, a Sanofi Company SNYNCT06838000 Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, aPneumococcal Infectionsactive not recruiting1268
2026-12-01 est.P1/P2Sanofi SNYNCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain Pandemic Influenza Immunization; Healthy Volunteersactive not recruiting720
2026-12-17 est.P2Sanofi SNYNCT06958536 A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseCrohn's Diseaserecruiting99
2026-12-17 est.P2Sanofi SNYNCT06975722 A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisUlcerative Colitisactive not recruiting105
2026-12-23 est.P2Sanofi SNYNCT06500702 A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental GlomeruFocal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesionrecruiting84
2027-01-07 est.P3Sanofi SNYNCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSickle Cell Diseaserecruiting100
2027-01-18 est.P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 YeaHuman Metapneumovirus Immunization; Respiratory Syncytial Virus Immunizationactive not recruiting1530
2027-01-19 est.P1/P2Sanofi SNYNCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSolid Tumorrecruiting542
2027-02-09 est.P2Sanofi SNYNCT07170917 Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativarecruiting208
2027-02-11 est.P2Sanofi SNYNCT06984627 A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseGraves' Diseaserecruiting30
2027-02-17 est.P3Sanofi SNYNCT07424144 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis Chronic Rhinosinusitis With Nasal Polypsactive not recruiting59

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-07-09FDA approvalapprovedSANOFI-AVENTIS U.S. LLC SNYSARCLISA ESCENAApproved 2026-07-09: SARCLISA ESCENA (BLA761445 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-29P2Sanofi SNYNCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LColitis Ulcerative; Crohn's Diseaseterminated7
2026-09-24P3Sanofi SNYNCT06834360 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic RhinosinusiChronic Rhinosinusitis With Nasal Polypsactive not recruiting216
2026-09-23P3Sanofi SNYNCT06834347 A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic RhinosinusiChronic Rhinosinusitis With Nasal Polypsactive not recruiting231
2026-09-22P2Sanofi SNYNCT06033833 Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of PrevAsthmaterminated335
2026-09-10P3Sanofi SNYNCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDChronic Obstructive Pulmonary Diseasecompleted669
2026-09-04P2Sanofi SNYNCT05039840 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting109
2026-08-06P2Sanofi SNYNCT06867094 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisColitis Ulcerativeterminated170
2026-08-05P2Sanofi SNYNCT06557772 A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseaseCoeliac Disease; Celiac Diseaseactive not recruiting229
2026-07-30P2Sanofi SNYNCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.Crohn's Diseaseterminated105
2026-06-10P3Sanofi SNYNCT06407934 A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 1Dermatitis Atopicactive not recruiting1541
2026-06-10P3Sanofi SNYNCT06290128 A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Polyneuropathy, Inflammatory Demyelinatinactive not recruiting109
2026-06-08P3Sanofi SNYNCT06687980 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged Lichen Simplex Chronicuscompleted138
2026-06-08P3Sanofi SNYNCT06687967 A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged Lichen Simplex Chronicuscompleted142
2026-05-22P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06744205 A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and OlderInfluenza; Healthy Volunteerscompleted1162
2026-05-22P3Sanofi SNYNCT05280548 A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseFabry Diseaseactive not recruiting104
2026-05-13P2Sanofi SNYNCT05731128 A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active UlceColitis Ulcerativeactive not recruiting68
2026-05-01P3Sanofi SNYNCT07135986 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaMeningococcal Infection; Healthy Volunteerscompleted1602
2026-04-16P1/P2Sanofi SNYNCT06695117 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose InactCOVID-19 Immunization; Influenza Immunizationcompleted980
2026-04-03P1/P2Sanofi SNYNCT06695130 Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant InfCOVID-19 Immunization; Influenza Immunizationcompleted980
2026-03-31P2Sanofi SNYNCT06691113 A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without NasChronic Rhinosinusitis Without Nasal Polypscompleted66
2026-03-24P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06727058 Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and OlderInfluenza Immunizationcompleted276
2026-03-02P3Sanofi SNYNCT06805513 Actual Use Trial of Tadalafil 5 mgErectile Dysfunctioncompleted2212
2026-03-02P3Sanofi SNYNCT04910776 Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaGlycogen Storage Disease Type IIactive not recruiting17
2026-02-27P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT06134648 Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidateRespiratory Syncytial Virus Infection; Healthy Volunteers; Human Metapneumoviruscompleted646
2026-02-23P2Sanofi SNYNCT06102005 Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaAsthmacompleted685
2026-02-12P2Sanofi SNYNCT06790121 A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe AtopicDermatitis Atopiccompleted150
2026-02-10P2Sanofi SNYNCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisColitis Ulcerativeactive not recruiting187
2026-01-29P2Sanofi SNYNCT06454240 A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis With Nasal Polypscompleted79
2026-01-20P3Sanofi SNYNCT07002060 Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in AdultsYellow Fever Immunizationcompleted640
2026-01-12P3Sanofi SNYNCT07079670 Safety and Immunogenicity of NVX-CoV2705COVID-19; SARS-CoV-2 Infectioncompleted676
2025-12-26P3Sanofi SNYNCT03485677 Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3Gaucher's Disease Type I; Gaucher's Disease Type IIIcompleted57
2025-12-25P3Sanofi Pasteur, a Sanofi Company SNYNCT07222059 Phase 3 Single Arm, Open Study on vYF in AdultsYellow Fevercompleted254
2025-12-22P2Sanofi SNYNCT05704049 A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Relapsed/Refractory Multiple Myelomaactive not recruiting118
2025-12-22P1/P2Sanofi SNYNCT05450562 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid TumorsNeoplasmterminated33
2025-12-17P3Sanofi SNYNCT05206773 A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseFabry Diseaseactive not recruiting122
2025-12-04P3Sanofi Pasteur, a Sanofi Company SNYNCT06252285 Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersRSV Immunisationterminated6300
2025-11-25P3Sanofi SNYNCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-Dermatitis Atopiccompleted589

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.